Elliott Won't Change Mind On Pharma. Merger

Jan 2 2014 | 11:48am ET

Elliott Management still has a week to tender its shares in pharmaceutical distributor Celesio, a move that would ensure that rival McKesson's US$8.3 billion offer for the company would succeed. But the activist hedge fund had no early Christmas presents for McKesson.

Elliott, which first announced its plans to block the merger earlier last month, reiterated its opposition on Dec. 23. "To be absolutely clear, Elliott's final, binding decision is not to accept McKesson's offer on its current terms."

The New York-based hedge fund made the statement following "reports suggesting that it will change its mind and accept McKesson's offer."

"These reports are categorically incorrect," Elliott said.

The hedge fund owns about 22.7% of Celesio's diluted stock, which should enable it to block the deal; McKesson has set a 75% hurdle for the merger to go through. It has said that the current price does not offer "fair compensation to all Celesio shareholders and bondholders," and has suggested splitting Celesio by selling its wholesale and pharmacy businesses separately.


In Depth

Royalties: The Alternative Assets of the Music Industry

Jul 8 2016 | 7:01pm ET

Recent market volatility has investors seeking greater insight into alternative...

Lifestyle

Vortic: Making Great American Watches Again

Jul 25 2016 | 6:29pm ET

If you are compelled by stories of entrepreneurial vision & drive, or simply...

Guest Contributor

MPI: Like Stellar Returns? Better Understand the Risks First

Jul 22 2016 | 8:44pm ET

When the press reports extraordinarily strong relative or risk-adjusted returns...